Patents Assigned to GlaxoSmithKline
  • Heterocyclic amides as kinase inhibitors
    Patent number: 9556152
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A, L, and B are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: January 31, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Philip Anthony Harris, Bryan Wayne King
  • Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
    Patent number: 9550785
    Abstract: The present invention relates to Compounds of formula (I) and salts thereof: wherein R1 is n-C3-6alkyl; R2 is hydrogen or methyl; R3 is hydrogen or C1-6alkyl, and m is an integer having a value of 0 to 3; are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: January 24, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Diane Mary Coe, Stephen Allan Smith
  • Multiple variants of meningococcal protein NMB1870
    Patent number: 9550814
    Abstract: Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: January 24, 2017
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Maurizio Comanducci, Mariagrazia Pizza
  • Compounds as diacylglycerol acyltransferase inhibitors
    Patent number: 9540400
    Abstract: This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: January 10, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Donghui Qin, Mui Cheung, Hemant Joshi, Raghuram Tangirala, Sridhar Reddy Bethi
  • Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
    Patent number: 9540383
    Abstract: Compounds of formula (I) and salts thereof: wherein R1 is n-C4-6alkyl or C1-2alkoxyC1-2alkyl-; R2 is hydrogen or methyl; each R3 is hydroxy, halo or n-C1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: January 10, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Diane Mary Coe, Stephen Allan Smith
  • Chemical compounds
    Patent number: 9533948
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: January 3, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • PURIFICATION OF STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR SACCHARIDES
    Publication number: 20160376301
    Abstract: The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.
    Type: Application
    Filed: September 7, 2016
    Publication date: December 29, 2016
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Paolo COSTANTINO, Maria Rosaria ROMANO, Francesco BERTI
  • Combination vaccines with serogroup B meningococcus and D/T/P
    Patent number: 9526776
    Abstract: Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: December 27, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Barbara Baudner, Derek O'Hagan, Manmohan Singh, Simone Bufali
  • Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
    Patent number: 9526777
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: December 27, 2016
    Assignees: The United States of America as Represented by the Department of Health and Human Services, Glaxosmithkline Biologicals SA
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS
    Publication number: 20160368911
    Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation.
    Type: Application
    Filed: July 1, 2014
    Publication date: December 22, 2016
    Applicant: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Sebastien Andre CAMPOS, John David HARLING, Afjal Hussain MIAH, Ian Edward, David SMITH
  • Benzonaphthyridine-containing vaccines
    Patent number: 9517263
    Abstract: The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) polymeric particles and (c) a benzonaphthyridine compound, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides, inter alia, methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: December 13, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Derek O'Hagan, Manmohan Singh, Siddhartha Jain, Sushma Kommareddy
  • INJECTABLE VACCINES AGAINST MULTIPLE MENINGOCOCCAL SEROGROUPS
    Publication number: 20160354457
    Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.
    Type: Application
    Filed: August 18, 2016
    Publication date: December 8, 2016
    Applicant: GlaxoSmithKline Biologicals SA
    Inventor: Paolo COSTANTINO
  • vaccine combination
    Patent number: 9511130
    Abstract: The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 6, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Laura Serino, Mariagrazia Pizza
  • Mixing lyophilised meningococcal vaccines with D-T-Pa vaccines
    Patent number: 9511132
    Abstract: A liquid D-T-Pa component is used to reconstitute a lyophilised meningococcal component, thereby producing a combined vaccine.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: December 6, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Mario Contorni
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9505745
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: November 29, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • Conjugates comprising an antigen and a carrier molecule
    Patent number: 9493517
    Abstract: The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a spr0096 antigen and a spr2021 antigen. spr0096 and spr2021 are Streptococcus pneumoniae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: November 15, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Paolo Costantino, Maria Rosaria Romano
  • Combined meningococcal conjugates with common carrier protein
    Patent number: 9492558
    Abstract: Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimizes the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunizing a patient against a disease caused by Neisseria meningitidis, wherein (1) the composition comprises conjugates for at least two of the four meningococcal serogroups A, C, W135 and Y, where at least two of the conjugates have a common carrier protein; and (2) the composition includes the common carrier in an unconjugated form at less than 10 ?g/ml.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: November 15, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Paolo Costantino
  • TRPV4 antagonists
    Patent number: 9487507
    Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: November 8, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
  • Compositions and methods
    Patent number: 9480735
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: November 1, 2016
    Assignees: Glaxo Group Limited, GlaxoSmithKline Biologicals, SA
    Inventors: Pascal Mettens, James Brown, Dennis Murphy
  • Package
    Patent number: D775945
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: January 10, 2017
    Assignee: GlaxoSmithKline, LLC
    Inventors: Leonard Joseph DiChiara, David Michael Lutness, Jeffrey Scott Brunner, Peter Kay, James Andrew Holt